State-by-State Snapshot for NPs: Key Takeaway for NPs : If youre in a full-practice state (or meet the experience threshold in states like IL or NY), you can prescribe GLP-1s and other weight-loss medications independentlyprovided youve documented the training/competence to do so
Effects of the disaccharidase inhibitor acarbose on meal and intravenous glucose tolerance in normal man
Pregnant or breastfeeding women, people with thyroid disorders, and those with seizure history should exercise particular caution before starting supplementation
The gallbladder is a small storage pouch located below the liver
Methodology and Sources This analysis is based on publicly available sources as of December 26, 2025: FDA communications: Compounding safety alerts, prescribing information, and regulatory guidance Novo Nordisk announcements: Wegovy pill approval, OASIS 4 trial results, pricing disclosures Independent reporting and primary sources: ABC News coverage and Novo Nordisks announcement on December 22, 2025 FDA oral Wegovy approval MEDVi terms and disclosures: Platform structure, pricing, and regulatory disclaimers Key Sources Cited: ABC News: "FDA approves Wegovy pill for weight loss" (December 22, 2025) Novo Nordisk: Official press release on FDA approval and OASIS 4 trial data (December 22, 2025) FDA Safety Communications: 20242025 alerts on compounded semaglutide dosing errors All regulatory references are based on FDA publications and third-party reporting available at the time of publication